Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

by Howard E. Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E. Olson, Charles R. Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A. Estes, David G. Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L. Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W. Wilson, Carolyn Peterson, R. Lee Mosley
Published 2017-03-01